We are live on ! Find out more
PBM icon

Psyence Biomedical

8 hedge funds and large institutions have $831K invested in Psyence Biomedical in 2024 Q1 according to their latest regulatory filings, with 8 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more ownership

Funds ownership: 0%0% (+0%)

Holders
8
Holders Change
+8
Holders Change %
% of All Funds
0.12%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
8
Increased
Reduced
Closed
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
CF
1
Cantor Fitzgerald
New York
$371K +$375K +90 New
AI
2
AdvisorShares Investments
Maryland
$309K +$305K +73 New
TSS
3
Two Sigma Securities
New York
$63.6K +$62.6K +15 New
VF
4
Virtu Financial
New York
$30K +$29.2K +7 New
CAC
5
Cowen and Company
New York
$28.5K +$29.2K +7 New
HF
6
HRT Financial
New York
$14K +$12.5K +3 New
Geode Capital Management
7
Geode Capital Management
Massachusetts
$12K +$12.5K +3 New
UBS Group
8
UBS Group
Switzerland
$2.69K +$4.17K +1 New
HT
9
Headlands Technologies
Illinois
$109
JP Morgan Chase
10
JP Morgan Chase
New York
$2

PBM Hedge Fund Activity: Q1 2024 in Review

8 of the 6,943 institutional investors tracked by Wall St. Rank reported a position in Psyence Biomedical (PBM) for Q1 2024, worth a combined $831K.

Buyers outnumbered sellers: 8 funds opened new PBM positions and 0 closed out — a net gain of 8 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Cantor Fitzgerald, opening a new position worth an estimated $375K.

  • 8 institutional investors held Psyence Biomedical (PBM) as of Q1 2024, up from 0 in Q4 2023.
  • Funds reported $831K of Psyence Biomedical stock for Q1 2024.
  • 8 funds opened new Psyence Biomedical positions in Q1 2024 and 0 closed out, a net change of +8 holders.
  • The largest Psyence Biomedical buyer in Q1 2024 was Cantor Fitzgerald, an estimated $375K added.

Based on aggregated 13F filings for Q1 2024.